title: Isolated regional perfusion for treatment of limb melanoma in the American black.
abstract: Since 1957, 961 patients with invasive malignant melanoma of the limbs were treated by regional perfusion. Forty-eight patients were black, representing 5 per cent of all patients with regional melanoma treated during this period. Thirty-one of the 48 patients were men, and 17 were women. Only 21 of the 48 patients had stage I lesions (M.D. Anderson classification), of whom 63 per cent had level IV or greater invasion. The average depth of invasion was 3.70 mm. Of 21 patients with stage III disease, 15 came to diagnosis with an intact primary lesion in addition to regional disease, and the majority of lesions arose on a plantar site with level V invasion. Eighty per cent of the patients had acral lentiginous melanoma. All melanoma patients were treated by isolated regional perfusion with wide excision of the primary plus regional lymph node dissection for biopsy-proven regional disease. At 10 years, survival rates were 71 per cent for stage I patients and 12.5 per cent for those with stage III disease. When black patients having had acral melanoma on a plantar or palmar site were compared with white patients of a similar stage of disease, however, it was found that black patients had equivalent long-term survival rates.
authors.affiliation: Department of Surgery, Tulane University School of Medicine, New Orleans, LA 70112.
authors.forename: J H
authors.initials: JH
authors.lastname: Muchmore
authors.forename: E T
authors.initials: ET
authors.lastname: Krementz
authors.forename: R D
authors.initials: RD
authors.lastname: Carter
authors.forename: C M
authors.initials: CM
authors.lastname: Sutherland
authors.forename: E G
authors.initials: EG
authors.lastname: Cieutat
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D044383:Black People; D010478:Chemotherapy, Cancer, Regional Perfusion; D005260:Female; D005534:Foot Diseases / Q000188:drug therapy*; D006225:Hand; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000401:mortality; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D011379:Prognosis
chemical_list: D000970:Antineoplastic Agents; D008558:Melphalan